Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha.

ABSTRACT: Cancer is one of the main causes of human mortality worldwide and novel chemotherapeutics are required due to the limitations of conventional cancer therapies. For example, using redox selenium compounds as novel chemotherapeutics seem to be very promising. The objective of this study was to explore if folate could be used as a carrier to deliver a newly synthesised selenium derivative selenofolate into cancer cells. Particularly, the cytotoxic effects of this selenofolate compound were investigated in a variety of cancer cell types including lung, liver, and cervical cancers and specifically IGROV1 cells. Our results showed that selenofolate inhibits the growth of cancer cells in-vitro. However, despite the expectations, folate receptor alpha (FRα) was not involved in the transport

SUBMITTER: Razaghi A 

PROVIDER: S-EPMC8209087 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature